Efficacy and safety of surufatinib in combination with CAPTEM for patients with advanced G2/G3 NETs: Updated results from a single-arm, phase II study

#4494

Introduction: Limited options exist for advanced G2/G3 NETs. While combined anti-angiogenic and chemotherapy has shown improved effect, the efficacy of surufatinib combined with CAPTEM for NETs remains under-explored.

Aim(s): Evaluating the efficacy and safety of surufatinib combined with CAPTEM in advanced G2/G3 NETs patients.

Materials and methods: We planned to enrol 50 advanced G2/G3 NETs patients, received ≤3 prior treatments. Patients received 250mg surufatinib p.o., qd daily, 850mg/m2 capecitabine p.o., bid on days 1-14, and 200mg/m2 temozolomide p.o., qd on days 10-14 in 28-day cycle. Cycling until they lost clinical benefit, occurred unacceptable toxicity, or agreed to withdraw. The primary endpoint was PFS (RECIST 1.1.); secondary endpoints were ORR, DCR, OS, and safety.

Conference:

Presenting Author: Wang W

Authors: Wang W, Liu Z, Yang X, Xue Z, Wei C,

Keywords: g2/g3 net, surufatinib, captem,